Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

RXRX.NASDAQ

Recursion Pharmaceuticals

Healthcare | Biotechnology

Biotechnology company using AI and cellular imaging to discover novel drugs through proprietary technology platform.

Flagship Insight

How Proprietary Biological Token Scarcity Is Redefining High-Performance Computing Valuations

A sharp divergence exists between traditional clinical-stage biotechnology valuations and the asset's emerging role as a sovereign biological data infrastructure monopoly. While high operational cash burn remains a primary near-term risk, geopolitical reshoring mandates and proprietary phenomic datasets drive long-term platform consensus.

Forecast TimelineUpdated On Jul 02 2026

Recursion Pharmaceuticals (RXRX) Stock Forecast and AI Rating

Recommendation

Hold & Monitor

Model signals are balanced; wait for clearer evidence.

2027

1-Year

NEUTRAL

$3.64

-4.2%

+16.4% IF INCL. DIVS

2029

3-Year

N/A

$5.59

+81%

2031

5-Year

NEUTRAL

$9.08

+139%

+195% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset represents a high-beta platform play positioned at the intersection of generative biology and high-performance computing. While the current macro regime of restrictive monetary policy and high capital costs penalizes its substantial operational cash burn, the long-term investment thesis hinges on the transition from a speculative clinical-stage biotech to an indispensable biological data utility. The integration of advanced chemistry engines and automated wet-lab infrastructure establishes a highly defensible, sovereign data moat that is increasingly valuable as frontier AI models face open-source training token exhaustion. This unique positioning allows the company to act as a critical infrastructure provider rather than a traditional binary drug developer.

Key insights

High operational cash burn of approximately four hundred million dollars annually requires disciplined capital allocation and creates near-term refinancing risks.
Geopolitical reshoring driven by legislative mandates funnels domestic pharmaceutical partnerships toward secure, US-based automated laboratories.
Proprietary multi-omic and phenomic datasets provide a structural competitive advantage over pure-software computational biology competitors.
Strategic compute subsidies and deep hardware partnerships insulate the platform from escalating infrastructure and silicon costs.
The primary risk remains the high historical attrition rate of clinical translation from in-silico models to human biology.
Long-term valuation depends on transitioning from lumpy milestone payments to high-margin, recurring platform licensing agreements.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Recursion Pharmaceuticals quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Recursion Pharmaceuticals.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$3.23	$3.6068	$4.37	$736.09
Quarter 2+6M	Jan 02, 2027	$2.907	$3.4871	$4.1496	$724.14
Quarter 3+9M	Apr 02, 2027	$2.1803	$3.5694	$4.5666	$713.57
Quarter 4+1Y	Jul 02, 2027	$1.9622	$3.5842	$5.6045	$723.38
Quarter 5+15M	Oct 02, 2027	$1.8641	$3.6409	$5.0441	$716.61
Quarter 6+18M	Jan 02, 2028	$1.7709	$3.7208	$5.8007	$738.34
Quarter 7+21M	Apr 02, 2028	$1.948	$3.9292	$6.4968	$746.91
Quarter 8+2Y	Jul 02, 2028	$1.7532	$4.2259	$9.0955	$771.93
Quarter 9+27M	Oct 02, 2028	$1.6655	$4.4944	$9.5502	$782.73
Quarter 10+30M	Jan 02, 2029	$1.7488	$4.79	$11.46	$807.31
Quarter 11+33M	Apr 02, 2029	$1.5739	$5.2335	$12.84	$822.72
Quarter 12+3Y	Jul 02, 2029	$1.4952	$5.5005	$15.15	$846.10
Quarter 13+39M	Oct 02, 2029	$1.4952	$5.5884	$13.93	$852.53
Quarter 14+42M	Jan 02, 2030	$1.57	$6.0332	$16.02	$882.91
Quarter 15+45M	Apr 02, 2030	$1.4915	$6.3862	$20.03	$900.46
Quarter 16+4Y	Jul 02, 2030	$1.4779	$6.8571	$22.03	$922.67
Quarter 17+51M	Oct 02, 2030	$1.3597	$7.4793	$25.34	$935.91
Quarter 18+54M	Jan 02, 2031	$1.2917	$7.9808	$28.38	$952.30
Quarter 19+57M	Apr 02, 2031	$1.2271	$8.5696	$30.65	$976.28
Quarter 20+5Y	Jul 02, 2031	$1.1044	$9.0782	$33.71	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in a profound structural categorization error: the market values the asset as a traditional clinical-stage biotechnology firm, assigning zero value to its core data infrastructure. While the crowd obsessively focuses on operating losses and clinical trial attrition, the variant perception recognizes the asset as a sovereign biological data monopoly. In an era where frontier artificial intelligence models are rapidly exhausting publicly available training data, the company's massive, proprietary, machine-readable phenomic and transcriptomic datasets represent a critical geopolitical and commercial chokepoint. The asset's true floor value is anchored by this irreplaceable data reservoir and its automated wet-lab infrastructure, which legacy pharmaceutical giants and technology hyperscalers will inevitably be forced to license to survive their own research failures and supply-chain decoupling.

Advisor Disagreement

The primary disagreement across the reports centers on the valuation framework and the competitive durability of the company's supercomputing infrastructure. Some perspectives argue that the proprietary dataset and automated wet labs represent an unassailable, sovereign monopoly that will inevitably command premium licensing fees. Conversely, more skeptical views suggest that the platform's hardware advantage is rapidly depreciating and easily replicated by mega-cap pharmaceutical companies deploying their own massive GPU clusters. Additionally, reports clash on the timing and severity of the impending dilution wall, with estimates of the cash runway varying based on assumed partnership milestone inflows.

Financial Reviews by iPulse AI

Earnings and financials

The company's financial reports show a classic high-risk, high-reward profile. On one hand, revenue is growing, but it is highly unpredictable because it depends on lumpy milestone payments from big pharmaceutical partners rather than steady, recurring sales. On the other hand, the company is losing massive amounts of money, with annual losses and cash spending running into hundreds of millions of dollars. Financial experts agree that this level of cash burn is highly dangerous, especially in today's high-interest-rate environment where borrowing or raising money is very expensive. While some believe that future licensing deals will eventually bring in highly profitable revenue, others warn that the company is a melting ice cube that will continue to lose money for the foreseeable future. Investors must accept that the company is structurally unprofitable today and relies entirely on outside funding to survive.

Profitability and margins

The company's current profit margins are deeply negative and structurally broken, as it spends far more on research and supercomputing than it makes in revenue. Traditional financial metrics like price-to-earnings ratios are completely useless here, as the company is priced entirely on its future potential rather than current profits. There is a sharp disagreement on when, or if, these margins will ever turn positive. Bullish outlooks suggest that if the company's operating system becomes the industry standard, profit margins will eventually explode to highly profitable, software-like levels. Bearish views, however, emphasize that the company is stuck in a high-cost model, burdened by the expensive physical realities of running clinical trials and maintaining hardware. Until the company can secure a massive, high-margin licensing deal that does not require expensive physical research, its margins will remain deeply in the red.

Balance sheet and leverage

At first glance, the company's balance sheet looks incredibly strong and safe. It holds a large amount of cash and has almost no traditional debt, which normally suggests a very safe financial position. However, financial experts agree that this safety is a temporary illusion. Because the company is spending cash at an extremely rapid rate, its large cash reserve is actually a ticking clock. Most assessments agree that the current cash will only last for another two to three years before the company runs out of money. In today's tough financial climate, raising new money will be very difficult and will likely force the company to issue new shares at a low price, which would hurt existing investors. While the clean balance sheet provides some short-term safety, the company's long-term survival depends entirely on securing new cash from partners before its runway ends.

Capex and investment intensity

The company is spending heavily on its future, pouring massive amounts of capital into building advanced supercomputers and automated robotic laboratories. This heavy spending is designed to create a massive data advantage that competitors cannot easily copy. However, opinions are split on whether this intense investment is a smart move. Optimists view this spending as a necessary step to build an unbeatable moat that will eventually pay off through high-margin licensing deals. Skeptics, however, warn that the technology is depreciating rapidly, meaning the company must constantly spend more money just to keep its computers up to date. Furthermore, because drug development takes many years, the payback on this heavy spending is highly uncertain. If these expensive computers do not quickly lead to successful drugs, this massive spending could turn out to be a major waste of shareholder capital.